Flipping Book - Hema

157 / 1498

First-line therapy with
chlorambucil, CVP, CHOP,
CHOP-like, fludarabine
combination, or rituximab
combination INDUCTION
90Y-ibritumomab
(n = 207)
Rituximab 250 mg/m2 IV on day −7
and day 0 +
90Y-ibritumomab
14.8 MBq/kg (0.4 mCi/kg)
[max 1184 MBq (32 mCi)] on day 0
CONSOLIDATION
NR
PD
CR/CRu
or PR
Not Eligible
R
A
N
D
O
M
I
Z
A
T
I
O
N
No further treatment
(n = 202)
CONTROL
Start of study
6-12 weeks after
last dose of induction
Patients with previously
untreated FL
Morschhauser et al. J Clin Oncol . 2008;26:5156-5164
Radioimmunotherapy consolidation FIT Study